You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
默沙東料新冠口服藥至明年底銷售或高達70億美元
阿思達克 10-29 09:13
默沙東(MRK.US)表示,若12月新冠口服藥Molnupiravir獲得美國授權,預計明年底的銷售額或達到介乎50億至70億美元。 行政總裁Robert Davis表示,上述預測只基於已簽署的合約以及即將達成的合約,相信銷售額有可能會更高。 默沙東表示,預計今年Molnupiravir的銷售介乎5億至10億美元,利潤將與合作夥伴Ridgeback 平分,同時今年將爲Molnupiravir生產1,000萬個療程,到明年產量將增加逾一倍。其生產目標不包括仿製藥的許可交易。 默沙東第三季收入增長20%至131.54億美元,持續經營業務的非公認會計準則(non-GAAP)每股盈利爲1.75美元。 季內抗癌藥物Keytruda銷售上升22%至至45.3億美元,優於市場預期,子宮頸癌疫苗「加衛苗」(Gardasil)的銷售亦增長68%。 默沙東將全年調整後每股盈利預測上調至5.65至5.7美元,高於原先料介乎5.47至5.57美元,當中不包括Molnupiravir的任何銷售貢獻。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account